Equities Analysts Set Expectations for SLNO Q4 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Lifesci Capital issued their Q4 2024 EPS estimates for Soleno Therapeutics in a research note issued to investors on Tuesday, February 4th. Lifesci Capital analyst M. Belghiti forecasts that the company will post earnings per share of ($0.37) for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.32) EPS, Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at $5.58 EPS, FY2028 earnings at $9.47 EPS and FY2029 earnings at $9.99 EPS.

A number of other research analysts have also recently commented on SLNO. Stifel Nicolaus reissued a “buy” rating and issued a $74.00 target price on shares of Soleno Therapeutics in a report on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Soleno Therapeutics in a report on Monday, December 2nd. Oppenheimer raised their price target on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a report on Monday, October 28th. Finally, Robert W. Baird restated an “outperform” rating and set a $72.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Stock Down 0.1 %

SLNO stock opened at $50.98 on Thursday. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $60.92. The company has a market cap of $2.20 billion, a PE ratio of -15.36 and a beta of -1.46. The business has a 50-day simple moving average of $47.33 and a 200 day simple moving average of $49.82.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its position in shares of Soleno Therapeutics by 21.5% during the third quarter. Janus Henderson Group PLC now owns 4,081,099 shares of the company’s stock worth $206,016,000 after purchasing an additional 722,226 shares in the last quarter. FMR LLC boosted its position in shares of Soleno Therapeutics by 6,048,754.5% during the third quarter. FMR LLC now owns 665,374 shares of the company’s stock worth $33,595,000 after acquiring an additional 665,363 shares during the last quarter. Westfield Capital Management Co. LP purchased a new position in Soleno Therapeutics during the third quarter valued at $25,028,000. TimesSquare Capital Management LLC bought a new stake in Soleno Therapeutics in the 4th quarter valued at $15,273,000. Finally, Wellington Management Group LLP lifted its stake in Soleno Therapeutics by 73.8% in the 3rd quarter. Wellington Management Group LLP now owns 683,170 shares of the company’s stock worth $34,493,000 after purchasing an additional 290,135 shares in the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Soleno Therapeutics news, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total value of $108,061.20. Following the completion of the sale, the insider now owns 76,605 shares of the company’s stock, valued at approximately $3,537,618.90. This trade represents a 2.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the completion of the transaction, the chief executive officer now directly owns 708,616 shares of the company’s stock, valued at approximately $32,178,252.56. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,360 shares of company stock valued at $790,119. Company insiders own 12.30% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.